0000921895-23-001765.txt : 20230731 0000921895-23-001765.hdr.sgml : 20230731 20230731193808 ACCESSION NUMBER: 0000921895-23-001765 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230726 FILED AS OF DATE: 20230731 DATE AS OF CHANGE: 20230731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ben-Tzvi Avraham CENTRAL INDEX KEY: 0001944721 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-13341 FILM NUMBER: 231129094 MAIL ADDRESS: STREET 1: 44 ZAYT SHEMEN ST. STREET 2: FLAT 4 CITY: EFRAT STATE: L3 ZIP: 9045544 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 4 1 form413531ben_07282023.xml OWNERSHIP DOCUMENT X0508 4 2023-07-26 0 0000910267 TITAN PHARMACEUTICALS INC TTNP 0001944721 Ben-Tzvi Avraham 44 ZAYT SHEMEN ST. FLAT 4 EFRAT L3 9045544 ISRAEL 1 0 0 0 0 Common Stock 2023-07-26 4 A 0 50000 0 A 50000 D Option to Purchase Common Stock 1.52 2023-06-29 4 A 0 25000 0 A 2032-08-15 Common Stock 25000 25000 D Option to Purchase Common Stock 1.31 2023-06-29 4 A 0 100000 0 A 2032-09-15 Common Stock 100000 100000 D The shares reported in this transaction represent Unrestricted Stock Awards pursuant to the Issuer's Fourth Amended and Restated 2015 Omnibus Equity Incentive Plan that vested immediately on the date of grant. The options were approved by the Issuer's Board of Directors on August 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on August 15, 2022. The options were approved by the Issuer's Board of Directors on September 15, 2022. The options were conditioned on the approval by the Issuer's stockholders of an increase in the number of shares available for issuance under the 2015 Omnibus Equity Incentive Plan, which approval occurred on June 29, 2023. The exercise price of the options is equal to the closing price of the Issuer's common stock on September 15, 2022. /s/ Avraham Ben-Tzvi 2023-07-31